Stay updated with breaking news from Massachusetts Based Third Harmonic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Third Harmonic Bio’s stock market debut was the only biotech IPO that crossed the $100 million threshold in the third quarter as the slowdown in IPO activity showed little sign of changing. Small deals continue to represent most of the IPO activity.
Third Harmonic Bio has filed to raise $150 million in a U.S. IPO, although the final figure may differ. Click here to read more about the THRD IPO here.
Third Harmonic Bio, which emerged from stealth early this year with a lead drug from Novartis and a $105 million round of funding, has not yet set any financial terms for its planned IPO. But the biotech plans to use the IPO cash for clinical early and mid-stage clinical tests of its small molecule in multiple inflammatory indications.